CLARKSVILLE, MD--(Marketwired - April 22, 2014) - Neuronascent, Inc. (www.neuronascent.com), a company focused on developing its novel therapeutic candidates for new neuron formation in Alzheimer's disease (AD), Parkinson's disease and Down syndrome, announced today that the company successfully completed a pre-investigational new drug (PIND) meeting with the FDA for their AD therapeutic candidate, NNI-362. These meetings are important to obtain FDA concurrence on Neuronascent's non-clinical, first-in-human clinical study and regulatory plans.
"This is one important milestone in reaching the ultimate goal of halting or reversing the progression of Alzheimer's in the approximately 35 million patients already suffering from the disease worldwide," said Judith Kelleher-Andersson, Ph.D., Founder and Chief Executive Officer of Neuronascent. Neuronascent was aided in the PIND meeting planning by National Institute on Aging (NIA). NIA is part of the U.S. Government's National Institutes of Health, and this PIND meeting support is part of NIA's broader translational research program for Alzheimer's disease.
NNI-362 is part of a larger molecular family that has been validated in animal models of aging and Alzheimer's disease, indicating that NNI-362 promotes an increase in new neurons in the hippocampus, correlating with cognitive benefit to normal brain levels. The hippocampus is one region selectively diminished in the brains of Alzheimer's patients due to progressive neurodegeneration.
Neuronascent, Inc. is a pre-IND stage company developing orally-available, novel neurorestorative therapeutics that target Alzheimer's disease, Parkinson's disease, Down syndrome, and post-traumatic stress disorder.
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.